History of research and development of immune checkpoint inhibitor anti-PD-1 antibody, nivolumab

被引：0
|
作者：
Yoshida, Takao [1 ]
机构：
[1] Ono Pharmaceut Co Ltd, Reserch Ctr Oncol, Osaka, Japan
来源：
CANCER SCIENCE | 2024年 / 115卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
SE2-4
引用
收藏
页码：693 / 693
页数：1
相关论文
共 50 条
  • [1] Toxicities of the anti-PD-1 immune checkpoint antibody nivolumab in the acute inpatient setting.
    Brito-Dellan, Norman
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (26)
  • [2] The efficacy of anti-PD-1 immune checkpoint inhibitor in nasopharyngeal carcinoma
    Park, Jong Chul
    Durbeck, Julia
    Boudadi, Karim
    Ho, Wen Jin
    Kang, Hyunseok
    ORAL ONCOLOGY, 2020, 108
  • [3] Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy
    Novotny, J. F., Jr.
    Cogswell, J.
    Inzunza, H.
    Harbison, C.
    Horak, C.
    Averbuch, S.
    ANNALS OF ONCOLOGY, 2016, 27 (10) : 1966 - 1969
  • [4] Safety of an anti-PD-1 immune checkpoint inhibitor in a liver transplant recipient
    Biondani, P.
    De Martin, E.
    Samuel, D.
    ANNALS OF ONCOLOGY, 2018, 29 (01) : 286 - 287
  • [5] Acute Lymphocytic Myocarditis With Anti-PD-1 Antibody Nivolumab
    Tadokoro, Tomonori
    Keshino, Eri
    Makiyama, Akitaka
    Sasaguri, Takakazu
    Ohshima, Koichi
    Katano, Harutaka
    Mohri, Masahiro
    CIRCULATION-HEART FAILURE, 2016, 9 (10)
  • [6] Innovative cancer immunotherapy, anti-PD-1 antibody Nivolumab
    Shibayama, Shiro
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2017, 133 (03) : S40 - S40
  • [7] Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
    Naidoo, J.
    Page, D. B.
    Li, B. T.
    Connell, L. C.
    Schindler, K.
    Lacouture, M. E.
    Postow, M. A.
    Wolchok, J. D.
    ANNALS OF ONCOLOGY, 2015, 26 (12) : 2375 - 2391
  • [8] Effect of anti-PD-1 antibody, nivolumab on early gastric cancer
    Koji Fukuda
    Taichi Yoshida
    Kazuhiro Shimazu
    Daiki Taguchi
    Masahiro Inoue
    Hiroshi Nanjyo
    Hiroyuki Shibata
    International Cancer Conference Journal, 2017, 6 (3) : 98 - 103
  • [9] Fatal toxicity induced by anti-PD-1 immune checkpoint inhibitor in thymic epithelial tumor
    Jing, Xuquan
    Zhu, Hui
    Li, Yuying
    Jia, Wenxiao
    Zhai, Xiaoyang
    Li, Ji
    Yu, Jinming
    IMMUNOTHERAPY, 2022, 14 (14) : 1097 - 1107
  • [10] Development of a human phage display-derived anti-PD-1 scFv antibody: an attractive tool for immune checkpoint therapy
    Sepideh Safaei Ghaderi
    Farhad Riazi-Rad
    Elmira Safaie Qamsari
    Salman Bagheri
    Fatemeh Rahimi-Jamnani
    Zahra Sharifzadeh
    BMC Biotechnology, 22
12345